BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The October 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a focus feature on those active in Neuro-partnering. This week, find out about how you can collaborate with PeptiDream.
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management.
Click here for more information on Alzheimer's partnering opportunities.
SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
HER2's new mutations Tim Fulmer doi:10.1038/scibx.2013.26 Washington University in St. Louis School of Medicine researchers have used next-generation sequencing to identify mutations in HER2 that are missed by standard screening tests. Based on the findings, the researchers are now recruiting patients with breast cancer expressing the mutations for a Phase II trial of Puma's HER2-targeting compound, neratinib. Full Text | PDF
Overcoming amantadine resistance Lauren Martz doi:10.1038/scibx.2013.27 A group of U.S. researchers has developed inhibitors of the influenza A virus M2 mutant that is responsible for most resistance to amantadine. InfluMedix has licensed the compounds and expects to bring a new influenza antiviral to the market within five years. Full Text | PDF
What to do with PKM2 Tracey Baas doi:10.1038/scibx.2013.28 Novartis has shown that the absence of pyruvate kinase M2 isozyme has no effect on cancer cell proliferation in mice, thus suggesting PKM2 inhibition alone might not be an effective strategy to stop tumor growth. Biotechs working on PKM2 modulators think it is too early to write off the target. Full Text | PDF
γ-Secretase lost and sound Lev Osherovich doi:10.1038/scibx.2013.29 Japanese and U.S. researchers have shown that inhibiting γ-secretase in the middle ear can promote hair cell regeneration and recovery from deafness in rodents. Keeping potentially toxic γ-secretase inhibitors confined to the ear will require formulation and delivery innovations. Full Text | PDF
Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) doi:10.1038/scibx.2013.30 In vitro and mouse studies identified small molecule MALT1 inhibitors that could help treat patients with the activated B cell (ABC) subtype of diffuse large B cell lymphoma (DLBCL). Full Text | PDF
Inhibitor of DNA binding 1 (ID1) doi:10.1038/scibx.2013.31 Patient sample, mouse and cell culture studies suggest inhibiting ID1 could help treat glioblastoma. Full Text | PDF
Phosphoinositide 3-kinase (PI3K); mammalian target of rapamycin (mTOR; FRAP; RAFT1); Janus kinase-2 (JAK-2) doi:10.1038/scibx.2013.32 In vitro and mouse studies suggest JAK-2 inhibitors could help increase the efficacy of PI3K and mTOR inhibitors against triple-negative breast cancer. Full Text | PDF
p53 doi:10.1038/scibx.2013.33 Cell culture and mouse studies suggest reducing dietary serine could help treat p53-deficient cancers. Full Text | PDF
Epidermal growth factor receptor (EGFR) doi:10.1038/scibx.2013.34 A high throughput screening study suggests the staurosporine-based research compound Gö6967 could aid the development of new treatments for NSCLCs with resistance mutations in EGFR. Full Text | PDF
Undecaprenyl diphosphate synthase (uppS) doi:10.1038/scibx.2013.35 In vitro and mouse studies identified inhibitors of uppS that could help treat bacterial infection. Full Text | PDF
Platelet factor 4 (PF4; CXCL4) doi:10.1038/scibx.2013.36 In vitro and mouse studies suggest small molecule mimetics of PF4 could help treat malaria. Full Text | PDF
Leukocyte cell-derived chemotaxin 2 (LECT2) doi:10.1038/scibx.2013.37 In vitro and mouse studies suggest LECT2 could help treat sepsis. Full Text | PDF
Peroxisome proliferation–activated receptor-γ coactivator 1α isoform 4 (PPARGC1A4; PGC-1α4) doi:10.1038/scibx.2013.38 Mouse studies suggest upregulating PGC-1α4 could help increase muscle mass. Full Text | PDF
Dopamine D2 receptor doi:10.1038/scibx.2013.39 In vitro and mouse studies suggest dopamine D2 receptor agonists could help treat neuroinflammation in diseases such as PD. Full Text | PDF
γ-Secretase; notch 1 (NOTCH1) doi:10.1038/scibx.2013.40 Studies in cell culture and in rodents suggest blocking NOTCH1 processing using g-secretase inhibitors could help treat hearing loss. Full Text | PDF
High throughput combinatorial screening to identify genotype-selective combination therapies for melanoma doi:10.1038/scibx.2013.41 High throughput combinatorial screening could be useful for identifying genotype-selective combination therapies to treat melanoma. Full Text | PDF
Hydrolysis-resistant proteins with Pictet-Spengler ligations doi:10.1038/scibx.2013.42 Pictet-Spengler ligations could be useful for creating hydrolysis-resistant biologics. Full Text | PDF
Computational algorithm for designing G protein–coupled receptor (GPCR) ligands against a predefined set of targets doi:10.1038/scibx.2013.43 A computational algorithm could be used to design GPCR ligands that modulate a predefined set of targets. Full Text | PDF
pH (low) insertion peptides (pHLIPs) for drug delivery to ischemic myocardium doi:10.1038/scibx.2013.44 pHLIPs could be useful for delivering imaging agents or therapeutics to ischemic regions of the heart that have lower pH values than nonischemic regions. Full Text | PDF
pH (low) insertion peptides (pHLIPs) for delivery of gold nanoparticles to tumors doi:10.1038/scibx.2013.45 pHLIPs could be used to target gold nanoparticles to tumors, which tend to have lower pH than normal tissue. Full Text | PDF
Chimeric antigen receptors (CARs) that require dual-antigen binding for activation doi:10.1038/scibx.2013.46 T cells engineered to express a CAR and a chimeric co-stimulatory receptor could enhance the tumor specificity of targeted T cell therapies. Full Text | PDF
Direct conversion of quiescent cardiomyocytes into pacemaker cells doi:10.1038/scibx.2013.47 A gene therapy approach for direct conversion of quiescent cardiomyocytes into pacemaker cells could be useful for treating arrhythmias. Full Text | PDF
Production of antibody-toxin fusion immunotoxins in algae doi:10.1038/scibx.2013.48 In vitro and mouse studies suggest algae chloroplasts could be used to produce anticancer immunotoxin fusion proteins. Full Text | PDF
Targeting ventral tegmental area (VTA) dopaminergic neurons to treat depression doi:10.1038/scibx.2013.49 Targeting a subset of dopaminergic neurons could be useful for reducing depression-related behaviors. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment